A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection

SARS-CoV-2, the causative agent of COVID-19(1), features a receptor-binding domain (RBD) for binding to the host cell ACE2 protein(1–6). Neutralizing antibodies that block RBD-ACE2 interaction are candidates for the development of targeted therapeutics(7–17). Llama-derived single-domain antibodies (...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tingting, Cai, Hongmin, Yao, Hebang, Zhou, Bingjie, Zhang, Ning, van Vlissingen, Martje Fentener, Kuiken, Thijs, Han, Wenyu, GeurtsvanKessel, Corine H., Gong, Yuhuan, Zhao, Yapei, Shen, Quan, Qin, Wenming, Tian, Xiao-Xu, Peng, Chao, Lai, Yanling, Wang, Yanxing, Hutter, Cedric A. J., Kuo, Shu-Ming, Bao, Juan, Liu, Caixuan, Wang, Yifan, Richard, Audrey S., Raoul, Hervé, Lan, Jiaming, Seeger, Markus A., Cong, Yao, Rockx, Barry, Wong, Gary, Bi, Yuhai, Lavillette, Dimitri, Li, Dianfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324831/
https://www.ncbi.nlm.nih.gov/pubmed/34330908
http://dx.doi.org/10.1038/s41467-021-24905-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324831/
https://www.ncbi.nlm.nih.gov/pubmed/34330908
http://dx.doi.org/10.1038/s41467-021-24905-z

Ejemplares similares